Shots:

• The P-III LUSTER-1 & 2 studies involve assessing of Fevipiprant (150/ 450mg) vs PBO in 894 & 877 patients aged ≥12yrs. in a ratio (1:1:1) with moderate-severe asthma- receiving GINA 4 and 5 SoC asthma therapy for 52wks. respectively
• The pooled analysis of P-III LUSTER 1 & 2 study did not support the further development of Fevipiprant for asthma as a primary indication- but it was well tolerated with AEs balanced across treatments groups
• Fevipiprant (qd) is an investigational- steroid-free therapy- act by blocking the DP2 pathway. Additionally- Novartis continues to invest in respiratory therapies with its respiratory portfolio including Xolair- Ultibro Breezhaler- QVM149

Click here to­ read full press release/ article | Ref: Novartis | Image: StraitTimes